
SCARD Pool report for 01-01-2004 to 31-12-2004

Participants	Doctors	11	
	Patients	184	
Specimens	New lesions	282	85.45%
	Previously biopsied lesions	48	14.55%
	Total lesions	330	100.00%

Breakdown of new versus previously biopsied specimens



Percentage of new lesions tested which were malignant	56.00%
Percentage of Definitively excised lesions that were malignant	63.06%
Lesions tested to find one melanoma (NNT)	4.17
Percentage of lesions tested for NMSC which were NMSC	66.67%
Ratio of New BCCs : New Melanomas	7:1

Accuracy

Diagnostic sensitivity

Melanomas	83.33% of 12
All NMSC	97.89% of 142
BCCs	97.73% of 88
SCCs	79.63% of 54

Positive predictive value

Melanomas	90.91% of 11
All NMSC	91.45% of 152
BCCs	56.58% of 152
SCCs	89.58% of 48

Adequacy

Percentage of definitively managed malignant cases where surgical margins were adequate


BCC	85.94% of 64
IEC/Bowens disease	62.50% of 8
SCC	77.78% of 27
Keratoacanthoma	100.00% of 2
Melanoma - in situ	80.00% of 10
Melanoma - invasive	100.00% of 2
Melanoma - invasive > 1mm	0% of 0
Other malignant	0% of 0

© 2026 SCARD Systems Pty Ltd

Lesion Breakdown

Histological Diagnosis

BCC (unspecified type)	25	8.80%
BCC - Superficial	26	9.15%
BCC - Nodular/Solid	30	10.56%
BCC - Aggressive	7	2.46%
IEC/Bowens disease	20	7.04%
SCC	31	10.92%
Keratoacanthoma	3	1.06%
Pinkus Fibroepithelioma	0	0%
Merkel cell tumour	0	0%
Other malignant	0	0%
NMSC Metastasis	0	0%
Melanoma - in situ	10	3.52%
Melanoma - invasive	2	0.70%
Melanoma - invasive > 1mm	0	0%
Melanoma - metastasis	0	0%
MELTUMP	0	0%
Naevus - other	10	3.52%
Naevus - dysplastic/Clark	17	5.99%
Naevus - blue	2	0.70%
Naevus - Spitz/Reed	0	0%
Naevus - Compound	0	0%
Solar keratosis	16	5.63%
Solar lentigo	2	0.70%
Seborrhoeic keratosis	39	13.73%
Lentigo Simplex	0	0%
Lichenoid keratosis (LPLK)	0	0%
Dermatofibroma	0	0%
Sebaceous gland hyperplasia	1	0.35%
Benign cyst	13	4.58%
Other benign	21	7.39%
Histology Pending	2	0.70%



© 2026 SCARD Systems Pty Ltd

Procedures

Definitive Surgical Management used to exclude melanoma

Ellipse	38	100.00%
Flap	0	0%
Graft - SSG	0	0%
Graft - FTSG	0	0%
No Closure	0	0%
Shave/Saucerisation	0	0%
Curettage & Cautery	0	0%
Liquid N2 freeze/thaw	0	0%
PDT	0	0%
Imiquimod	0	0%
5 FU cream	0	0%
GP referral	0	0%
Specialist referral	0	0%
Other	0	0%

Biopsy used to exclude melanoma

Punch - sample	3	25.00%
Shave - sample	0	0%
Incisional	0	0%
Punch - removal	1	8.33%
Shave - removal	2	16.67%
Excisional	6	50.00%
Curettage	0	0%
Other	0	0%

Breakdown of definitive management procedures for malignant conditions

Ellipse	97	59.88%
Flap	1	0.62%
Graft - SSG	0	0%
Graft - FTSG	0	0%
No Closure	0	0%
Shave/Saucerisation	9	5.56%
Curettage & Cautery	27	16.67%
Liquid N2 freeze/thaw	1	0.62%
PDT	0	0%
Imiquimod	5	3.09%
5 FU cream	0	0%
GP referral	0	0%
Specialist referral	22	13.58%
Other	0	0%

Breakdown of definitive management procedures for benign conditions

Ellipse	70	88.61%
Flap	0	0%
Graft - SSG	0	0%
Graft - FTSG	0	0%
No Closure	0	0%
Shave/Saucerisation	3	3.80%
Liquid N2 freeze/thaw	0	0%
5 FU cream	0	0%
GP referral	0	0%
Specialist referral	0	0%
Other	0	0%

© 2026 SCARD Systems Pty Ltd

Procedures (continued)


Percentage of procedures/closures that were complex

Complex Closures	0% of 96
Complex Closures (inc Curettage & Cautery)	0% of 102

Locations

Breakdown of melanomas by location and percentage melanomas of total lesions at that location

Nose	0	0% of 10
Lip	0	0% of 3
Ear	0	0% of 7
Eyelid	0	0% of 0
Other face	2	4.55% of 44
Scalp	0	0% of 9
Neck	0	0% of 21
Shoulder	1	7.69% of 13
Chest	1	6.67% of 15
Abdomen	0	0% of 6
Genitalia	0	0% of 0
Back	4	7.84% of 51
Buttock	0	0% of 0
Arm	1	6.25% of 16
Forearm	1	4.55% of 22
Hand Dorsal	0	0% of 10
Hand Palmar	0	0% of 1
Finger Dorsal	0	0% of 6
Finger Nail	0	0% of 0
Finger Palmar	0	0% of 0
Thigh	0	0% of 15
Leg	2	6.90% of 29
Foot Dorsal	0	0% of 3
Foot Plantar	0	0% of 1
Toe Dorsal	0	0% of 0
Toe Nail	0	0% of 0
Toe Plantar	0	0% of 0
Palm Or Sole	0	0% of 0



© 2026 SCARD Systems Pty Ltd